Charcot-Marie-Tooth Association

[Not Yet Scheduled]
The CMTA STAR (Strategy to Accelerate Research) Consortium was launched as a means to facilitate collaboration and accelerate therapy development for scientists, clinical researchers and pharmaceutical companies working on Charcot-Marie-Tooth neuropathy disorders. CMT disorders taken together have a disease frequency of 1:2500, are of known genetic causation, and lack available therapies, making them attractive candidates for therapy development.

The CMTA has assembled preclinical “toolboxes” for different CMT disorders, allowing proof-of-principle testing of the role of a therapeutic target in the disease process, and of the ability of a therapy directed to this target to arrest or even reverse the pathology. Alliances are conducted via a broad CMT expert and pharmaceutical testing network that includes services for study planning and project execution, therapy evaluation via a network of leading specialty CRO’s, and straightforward agreements for protecting and sharing data.
Company Type:
Advocacy/Non-Profit/Other
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
1983
Main Therapeutic Focus:
Lead Product in Development:
Not Provided
Development Phase of Primary Product:
Not Provided
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Founder
HumanFirst Therapeutics LLC